诚达药业
(301201)
| 流通市值：18.63亿 | | | 总市值：33.06亿 |
| 流通股本：8719.38万 | | | 总股本：1.55亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 76,307,845 | 333,131,182.38 | 243,768,662.64 | 164,012,180.77 |
| 营业收入 | 76,307,845 | 333,131,182.38 | 243,768,662.64 | 164,012,180.77 |
| 二、营业总成本 | 80,611,623.48 | 393,073,140.12 | 235,403,173.38 | 164,252,771.69 |
| 营业成本 | 39,627,889.42 | 190,482,603.64 | 137,620,876.91 | 99,639,206.77 |
| 税金及附加 | 424,558.48 | 4,281,592.87 | 2,274,425.31 | 2,168,239.69 |
| 销售费用 | 846,362.73 | 4,634,529.09 | 3,337,089.69 | 2,176,166.47 |
| 管理费用 | 30,808,110.88 | 104,004,017.1 | 65,621,516.21 | 44,124,262.7 |
| 研发费用 | 9,022,289.07 | 93,709,619.64 | 29,780,273.67 | 19,112,923.27 |
| 财务费用 | -117,587.1 | -4,039,222.22 | -3,231,008.41 | -2,968,027.21 |
| 其中:利息费用 | 605,056.97 | 295,338.26 | - | 12,364.42 |
| 其中:利息收入 | 485,623.61 | 2,026,669.84 | 1,668,431 | 1,212,490.8 |
| 加:公允价值变动收益 | 477,755.54 | 1,603,689.96 | 4,972,835.53 | 3,664,720.51 |
| 加:投资收益 | 4,117,751.42 | 30,786,457.23 | 23,819,115.33 | 18,833,376.8 |
| 资产处置收益 | 34,493.74 | 204,739.69 | 204,739.69 | 129,452.19 |
| 资产减值损失(新) | -607,002.4 | -7,841,866 | -3,628,172.55 | -1,117,463.06 |
| 信用减值损失(新) | -1,850,222.64 | 4,755,949.59 | 5,975,640.27 | 4,445,643.97 |
| 其他收益 | 675,010.67 | 5,863,422.96 | 4,994,849.34 | 1,873,074.6 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -1,455,992.15 | -24,569,564.31 | 44,704,496.87 | 27,588,214.09 |
| 加:营业外收入 | 625.47 | 60,865.27 | 11,713.64 | 6,163.74 |
| 减:营业外支出 | 80,313.42 | 2,674,358.85 | 2,279,295.31 | 1,337,869.59 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -1,535,680.1 | -27,183,057.89 | 42,436,915.2 | 26,256,508.24 |
| 减:所得税费用 | -203,098.49 | 456,104.52 | 1,900,652.89 | 1,048,688.45 |
| 六、净利润 | -1,332,581.61 | -27,639,162.41 | 40,536,262.31 | 25,207,819.79 |
| 持续经营净利润 | -1,332,581.61 | -27,639,162.41 | 40,536,262.31 | 25,207,819.79 |
| 归属于母公司股东的净利润 | -1,399,981.98 | -28,103,664.37 | 40,392,784.63 | 25,174,792.07 |
| 少数股东损益 | 67,400.37 | 464,501.96 | 143,477.68 | 33,027.72 |
| (一)基本每股收益 | -0.01 | -0.18 | 0.27 | 0.17 |
| (二)稀释每股收益 | -0.01 | -0.18 | 0.27 | 0.17 |
| 八、其他综合收益 | - | -19,201,500 | - | - |
| 归属于母公司股东的其他综合收益 | - | -19,201,500 | - | - |
| 九、综合收益总额 | -1,332,581.61 | -46,840,662.41 | 40,536,262.31 | 25,207,819.79 |
| 归属于母公司股东的综合收益总额 | -1,399,981.98 | -47,305,164.37 | 40,392,784.63 | 25,174,792.07 |
| 归属于少数股东的综合收益总额 | 67,400.37 | 464,501.96 | 143,477.68 | 33,027.72 |
| 公告日期 | 2025-04-25 | 2025-04-25 | 2024-10-29 | 2024-08-28 |
| 审计意见(境内) | | 标准无保留意见 | | |